

Poster presentation

Applications of sensitivity analysis for drug discovery and development in the ErbB receptor network

B Harms*¹, A Lee², R Paxson*², UB Nielsen¹ and B Schoeberl¹

Address: ¹Merrimack Pharmaceuticals Inc., Cambridge MA, USA and ²The MathWorks Inc., Natick MA, USA

Email: R Paxson* - Pax.Paxson@mathworks.com

* Corresponding authors

from BioSysBio 2007: Systems Biology, Bioinformatics and Synthetic Biology
Manchester, UK. 11–13 January 2007

Published: 8 May 2007

BMC Systems Biology 2007, 1(Suppl 1):P74 doi:10.1186/1752-0509-1-S1-P74

This abstract is available from: <http://www.biomedcentral.com/1752-0509/1?issue=S1>

© 2007 Harms et al; licensee BioMed Central Ltd.

Receptor-mediated signaling networks are very attractive targets for the development of oncology therapeutics. However, the complexity of these networks, characterized by redundancy, cross-talk, and non-linearity, hinders the generation of reliable qualitative insight into how to develop the most effective therapeutic and deliver it to the right patient.

We are using quantitative biochemical network models of receptor signaling to yield significant improvements in drug design and decision-making throughout the development of our therapeutics. As an example, we have developed a model of the ErbB receptor network that includes ErbB1-4, ligand-receptor binding of different ErbB ligands, receptor trafficking, and intracellular signal transfer leading to ERK and Akt phosphorylation. The model is first trained using quantitative experimental data and then our *in silico* predictions are verified by an independent set of experiments.

Using this validated biochemical network model, we present methodologies for using local and global sensitivity analyses as *in silico* drug discovery tools. The application of sensitivity analysis allows us to gain quantitative insights into important issues including network topology and the importance of cellular heterogeneity with respect to protein expression. We show how these insights find application in drug targeting and biomarker identification.